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Abstract: OnabotulinumtoxinA, a neurotoxin, has been studied in numerous trials as a 
novel preventive therapy for migraine headache. The data would support that it may be effec-
tive at reducing headache days in patients suffering from chronic migraine ($15 headache 
days/month, with eight or more of those migraine headache days). The mechanism by which 
onabotulinumtoxinA exerts its effects on migraine is not yet understood. It is known to inhibit 
acetylcholine release at the neuromuscular junction, but this probably does not explain the 
observed antinociceptive properties noted in preclinical and clinical trials. This review will 
discuss the known mechanisms of action of botulinum toxin type A, and will review the available 
randomized, placebo-controlled trials that have looked at its efficacy as a migraine preventative. 
We also describe the onabotulinumtoxinA injection sites used at our institution.
Keywords: botulinum toxin, prophylaxis, onabotulinumtoxinA, mechanism, migraine, 
prevention
Introduction
Migraine is a debilitating primary headache disorder characterized by recurrent 
headaches typically described as unilateral, pulsating, moderate, or severe. They 
are aggravated by physical activity and associated with nausea and/or sensitivity to 
light and sound.1 Though it is often conceptualized as a continuum or spectrum dis-
order, migraine is divided into two subtypes based on attack frequency: episodic and 
chronic. In episodic migraine, attacks occur on less than 15 days each month, whereas 
in chronic migraine a patient has at least 15 headache days each month, and at least 
eight of those are migraine headaches (see Table 1).2,3 Each year, 3%–14% of episodic 
headache sufferers convert to chronic headache sufferers.1 Compared with episodic 
migraine sufferers, patients with chronic migraine have a lower socioeconomic status, 
reduced health-related quality of life, greater psychiatric and medical comorbidities, 
and increased occupational disability.4
The main aim of preventive migraine therapy is to reduce the frequency, duration, 
and/or severity of migraine attacks. There are many preventive therapies available, 
including β-adrenergic blockers, antidepressants, calcium channel blockers, and 
anticonvulsants.5 Unfortunately, many of the current options are of limited benefit 
and can be associated with potentially serious side effects.6 There is therefore great 
demand for alternative preventive therapies that are effective and well tolerated, with 
limited systemic effects.6
Botulinum toxin type A (BT-A) was first reported as a potential migraine therapy 
by Binder et al7 in 1991, when they observed that the patients receiving pericranial Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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BT-A injections for facial hyperfunctional lines experienced 
relief of migraine headache symptoms. A nonrandomized, 
open-label study suggesting that BT-A could possibly be a 
safe and effective migraine treatment soon followed.7,8 Since 
then, great interest has prevailed in this pharmaceutical 
as a potential treatment for migraine. While investigating 
its efficacy as a migraine preventive, there have also been 
efforts to establish the mechanism by which botulinum toxin 
might exert an analgesic effect.
The goal of this review is to discuss the known mecha-
nisms of action of BT-A, and then discuss the evidence 
behind its use in the treatment of migraine. As pointed out 
by Dressler and Benecke9 in a recent review, there is some 
discrepancy in the abbreviations used in the literature for 
these types of discussions. For our purposes, we will use the 
neurotoxin abbreviation (BoNT-A) for discussion of mecha-
nism of action at the level of the neuromuscular junction, and 
then use the therapeutic preparation botulinum toxin type A 
abbreviation (BT-A) for discussions of preclinical and clini-
cal trials. At the time of this article, only BT-A in the form 
of onabotulinumtoxinA has been approved by the US Food 
and Drug Administration (FDA) for the treatment of chronic 
migraine. Therefore, our discussion of clinical efficacy 
will focus primarily on published data from randomized, 
double-blind, placebo-controlled trials examining the use of 
onabotulinumtoxinA in migraine prophylaxis.
Pharmacology of botulinum toxin
Strains from the gram-positive anaerobic bacteria   Clostridium 
botulinum are known to produce seven serologically distinct 
neurotoxins: A, B, C1, D, E, F, and G (C2 is not considered 
a neurotoxin).10 Currently, only the A and B serotypes are 
used for commercial purposes, though others have been 
used experimentally in humans.11,12 Because of differences 
in production, the commercially available botulinum toxin 
preparations each have distinct pharmacokinetics. The 
potency units are specific to each product, and the doses 
cannot be compared or converted from one botulinum prod-
uct to another. To reinforce these individual potencies and 
prevent medication errors, the FDA has revised the classifi-
cation of botulinum toxin products to include the following 
generic names: onabotulinumtoxinA (marketed as BOTOX®/
BOTOX® Cosmetic, Allergan Inc, Irvine, CA), rimabotu-
linumtoxinB (MYOBLOC®, Solstice Neurosciences Inc, 
Louisville, KY), abobotulinumtoxinA (Dysport®, Medicis 
Pharmaceuticals, Scottsdale, AZ), and incobotulinumtoxinA 
(XEOMIN®, Merz Pharmaceuticals, Greensboro, NC).13,14
Therapeutic preparations of BT-A come as powders 
that have to be reconstituted with 0.9% NaCl/H2O before 
use. Most BT-A preparations consist of the botulinum 
toxin   (neurotoxin and nontoxic complexing proteins) and 
  excipients.9 IncobotulinumtoxinA is slightly different, in 
that it has no complexing proteins.15 With food-borne botu-
lism, the complexing proteins are thought to help protect the 
protein from acids and proteases in the gastrointestinal tract, 
and may help the toxin cross the intestinal barrier to enter 
circulation. The role of complexing proteins in commercial 
preparations of injectable botulinum toxin is not clear.15 
The active neurotoxin molecule is made up of a heavy chain 
(100 kDa) and a light chain (50 kDa), joined by a disulfide 
bond (see   Figure 1). The heavy chain acts as the binding and 
translocation domain, and the light chain is the enzymatically 
active zinc (Zn++)-dependent endopeptidase.16,17
Method of action
Action at the neuromuscular junction
The most well-known mechanism of action is at the presyn-
aptic nerve terminal, where the toxin prevents the calcium-
dependent release of acetylcholine.18 There are four main 
steps in this process: binding to the acceptor on the plasma 
membrane, internalization of the botulinum toxin, separation 
of the light and heavy chain with escape of the light chain 
Table 1 Criteria for migraine without aura and chronic migraine 
(from the international Headache Society)2,3
i.  Migraine without aura:
  At least five attacks fulfilling the following criteria:
  A. Headaches lasting 4–72 hours (treated or untreated)
  B. At least two of the following characteristics:
    a. Unilateral location
    b. Pulsating or throbbing quality
    c. Moderate or severe pain intensity
    d.   Aggravation by or causing avoidance of routine physical activity 
(eg, walking or climbing stairs)
  C. During headache, at least one of the following:
     a. Nausea and/or vomiting
     b. Photophobia and phonophobia
  D. Not attributed to another disorder
ii. Chronic migraine (revised international Headache Society criteria):
  A.   Headache (tension-type and/or migraine) on $15 days per month 
for at least 3 months
  B.   Occurring in a patient who has had at least five attacks fulfilling 
criteria for migraine without aura
  C.   On $8 days per month for at least 3 months headache has fulfilled 
criteria for pain and associated symptoms of migraine without aura 
(iA–iD above) and/or has treated and relieved their pain with a triptan 
before the expected development of the symptoms (listed in iA–iD)
  D.   No medication overuse (use of ergotamine, triptans, opioids, or 
combination analgesics more than 9 days/month for more than  
3 months) and not attributed to another causative disorderNeuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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into the cytosol, and light-chain inhibition of the docking/
fusion of the synaptic vesicles containing acetylcholine.19 
These steps are illustrated in Figure 1 and are described in 
further detail in this section.
The C-terminal of the heavy chain is responsible for inter-
acting with a high-affinity ganglioside acceptor outside of the 
nerve terminal.18 This acceptor is felt to be an intraluminal 
vesicular protein that has become exposed to the outside 
of the nerve terminal as part of the recycling/exocytosis 
of   vesicles.18 This induces endocytosis of the botulinum 
  neurotoxin (BoNT) into the nerve terminal, where it is con-
tained within a membrane-bound synaptic vesicle. The fact 
that BoNT may depend on the recycling of vesicles to gain 
entry has been proposed as an explanation for why BoNT 
seems to be more effective in blocking neuromuscular junc-
tions when the target muscle is active.17,18,20,21 Next, the acidic 
Figure 1 Mechanism of botulinum neurotoxin type A (BoNT-A) at the neuromuscular junction. (A) Normal neurotransmitter release requires fusion of the vesicle membrane 
to the membrane of the presynaptic nerve terminal. This process is guided by the fusion of three proteins that make up the soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARe) complex: the vesicle-associated membrane protein (vAMP or synaptobrevin) and the membrane-bound syntaxin and synaptosome-
associated protein of 25 kDa (SNAP-25). ACh is released from the vesicle, diffuses across the synaptic cleft, and binds to the acetylcholine (Ach) receptor, resulting in normal 
muscular contraction. (B) The heavy chain of BoNT-A binds to a ganglioside acceptor in the plasma membrane of the presynaptic nerve terminal. This leads to receptor-
mediated endocytosis of the neurotoxin. The acidic environment of the synaptic vesicle or endosome leads to a conformational change in the toxin and eventual reduction of 
the linking disulfide bond, freeing the light chain. The light chain translocates to the cytosol and cleaves the C-terminal of the SNAP-25 protein. This inhibits SNARE complex 
formation and therefore inhibits neurotransmitter release.
Note: Used with permission of Mayo Foundation for Medical education and Research, all rights reserved.Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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environment of the vesicle induces a conformational change 
of the toxin, with eventual breaking of the disulfide bond. 
This allows the light chain to escape the vesicle into the 
cytosol.18,22 The light chain then cleaves one of three core pro-
teins that comprise the soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) complex and 
that are involved in vesicle docking/fusion during regu-
lated exocytosis. The three core SNARE proteins include 
vesicle-associated membrane protein (VAMP; also known 
as synaptobrevin), syntaxin, and synaptosomal-associated 
protein of 25 kDa (SNAP-25).23 Each immunologically 
distinct BoNT serotype has a unique site of action within 
the SNARE complex (BoNT-C1 actually has two sites of 
action). Synaptobrevin/VAMP is cleaved by BoNT types B, 
D, F, and G. Syntaxin is cleaved by BoNT type C1. SNAP-25 
is cleaved by BoNT types A, E, and C1.24 By inhibiting the 
release of acetylcholine, BoNT leads to chemical denervation 
and muscle paralysis. Recovery from toxin-induced paralysis 
involves resprouting of new terminals from the motor neuron, 
followed by slow recovery of the original nerve terminal’s 
ability to release acetylcholine.25 For BoNT-A, the clinical 
effect terminates in about 2–6 months in humans.26
Antinociceptive action
Early in the use of botulinum toxin for motor conditions, 
investigators noted that the pain relief preceded, and in 
some cases was greater than, the objective motor benefit; 
suggesting that the effect on pain probably involved more 
than just neuromuscular blockade.19,27 The antinociceptive 
action of BT-A, and the effect on migraine, is poorly under-
stood; but the effect may be multifactorial with effects on 
muscle fibers, autonomic fibers, and possibly pain fibers. 
BT-A appears to have an effect on peripheral sensitization 
and may also have an effect (either direct or indirect) on the 
central processing of pain.27,28
Action at other cholinergic nerve terminals
The neuromuscular blockade just described is a result of 
blocking the α-motor neurons innervating the extrafusal 
muscle fibers, which are the fibers responsible for the actual 
contractile property of the muscle. However, BT-A is also 
known to block transmission of γ-motor neurons to the intra-
fusal fibers in muscle spindles.17 As muscle spindles provide 
afferent information about muscle stretch to the central 
nervous system (CNS), some authors have suggested that 
reducing their input may attenuate the hyperactivity of the 
muscle involved in tonic muscle contractions, and may in this 
way contribute to some of the pain relief observed.29,30
In addition to the somatic motor neurons (α and γ), BT-A 
interferes with transmission of acetylcholine in the autonomic 
nervous system. By blocking the preganglionic nerve termi-
nals of the sympathetic and parasympathetic nerve terminals, 
as well as many of the postganglionic fibers, botulinum toxin 
has a complex effect on autonomic function. In botulism, this 
effect can lead to symptoms of anhidrosis,   xerophthalmia, 
xerostomia, orthostatic hypotension, gastrointestinal paraly-
sis, and urinary retention. Therapeutically, this effect has 
made botulinum toxin a useful therapy for hyperhidrosis 
and hypersalivation. Many of the autonomic nerve terminals 
affected by botulinum toxin have other neuropeptides colocal-
ized with acetylcholine, such as substance P, somatostatin, 
enkephalins, norepinephrine, adenosine triphosphate, neu-
ropeptide Y, and nitric oxide.30 Some authors hypothesize 
that the effect of BT-A on the autonomic nervous system, 
particularly the effect on autonomic vascular control, may 
allow the toxin to interfere with neurogenic inflammation 
and associated pain.30
Noncholinergic nerve terminals
In vitro and in vivo studies have demonstrated that if BT-A 
is introduced into noncholinergic nerve terminals, it can 
block the calcium-dependent release of neurotransmitters 
other than acetylcholine.17,27,28 BT-A has been found to 
block the release of inflammatory pain mediators such as 
substance P from cultured dorsal root ganglion neurons. It 
has also been shown to reduce potassium-stimulated, but 
not basal, release of calcitonin gene-related peptide (CGRP) 
from cultured trigeminal ganglia neurons.31,32 It has also been 
shown to block the release of glutamate from peripheral 
nerve terminals in inflammatory pain models.33
Inflammatory and neuropathic pain models
In rat models of inflammatory pain, peripherally applied 
BT-A has been shown to be effective in reducing the asso-
ciated pain behaviors. Cui et al33 examined the effect of 
BT-A on the formalin model of inflammatory pain. In this 
model, a chemical irritant (formalin) is injected into the 
hind paw of a rat. This results in a reproducible biphasic 
response involving pain behaviors and excitation of dorsal 
horn   neurons. Phase I (first 5 minutes after injection) is 
thought to be caused by direct activation of the peripheral 
small afferent fibers by formalin. Following a quiet phase, 
phase II (15–60 minutes) is attributed to sensitization of the 
peripheral afferents by inflammatory mediators. Pretreat-
ment with BT-A was shown to produce a dose-dependent 
reduction in   nociceptive   behaviors during phase II.33 Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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Further study showed that this reduction in pain behavior 
was associated with a dose-dependent reduction of the 
excitability of the dorsal horn (as measured by Fos-like 
immunoreactivity) and of the formalin-mediated activity in 
the dorsal horn wide-dynamic-range neurons. There was no 
effect on acute pain behavior during phase I, which agrees 
with previous studies showing that BT-A has no direct 
effect on acute noninflammatory nociception.27,34 In other 
inflammatory pain models, BT-A pretreatment (6 days) also 
significantly reduced the enhanced sensitivity to mechanical 
and thermal stimuli provoked by peripheral carrageenan or 
capsaicin injections in rats.35
Animal models have also examined the effect of BT-A in 
neuropathic pain models. Bach-Rojecky et al36 demonstrated 
that a peripheral injection of BT-A significantly reduced 
thermal and mechanical hyperalgesia associated with the 
neuropathy induced by partial sciatic nerve transection in 
rats. Similar to other studies, there was no direct antinoci-
ceptive effect, as the BT-A had no effect on the thermal and 
mechanical sensation of sham-operated animals.36 Pavone 
and Luvisetto28 also found a dose-dependent reduction 
in mechanical allodynia and cold hyperalgesia following 
chronic constriction injury of the sciatic nerve. The effect 
on allodynia was present only if BT-A was given after nerve 
injury, suggesting that BT-A could reduce neuropathic symp-
toms but not protect against the neuropathy. A similar effect 
was present if the BT-A was injected intrathecally.37 Not only 
does BT-A affect pain behaviors associated with chronic 
constriction injury of the sciatic nerve but also it was found 
to diminish the expected injury-induced upregulation of neu-
ropeptides (eg, prodynorphin and pronociceptin) and nitric 
oxide synthase1 mRNA in the rat dorsal root ganglia.38
Human trials may also support BT-A having an analgesic 
effect in neuropathic pain. In a recent study, Ranoux et al39 
used a randomized, double-blind, placebo-controlled trial to 
examine the effect of BT-A on allodynia associated with focal 
neuropathies. They found that a single intradermal injection 
of BT-A reduced the intensity and area of mechanical allo-
dynia and cold pain thresholds on the affected side, with no 
change in perception thresholds. This effect seemed to persist 
from 2 weeks to 14 weeks after injection.
Possible central action of BT-A
While studying the effect of BT-A on paclitaxel-induced neu-
ropathy in rats, Favre-Guilmard et al40 noted that injection of 
BT-A in the hindpaw almost completely abolished the mechan-
ical hyperalgesia not only in the injected paw but also in the 
contralateral paw. This bilateral   antinociceptive effect remained 
stable over the 6 days of observation. The mechanism behind 
this bilateral effect was unclear, but the authors pointed out 
that a systemic diffusion effect was unlikely, as a contralateral 
injection of BT-A did not elicit an antihyperalgesic effect in 
their model of carrageenan-induced hyperalgesia or in previ-
ous models of formalin-induced pain.40 They proposed that the 
mechanism might involve more complex processes such as 
central sensitization.   Bach-Rojecky et al41 observed a similar 
bilateral antinociceptive effect while studying the effect of a 
single injection of BT-A on streptozotocin-induced diabetic 
neuropathy in rats. Other studies have found that peripheral 
injections of BT-A in the cranial region can affect associ-
ated brainstem nuclei. For instance, BT-A injected into the 
cat lateral rectus muscle can have dose-dependent structural 
and functional effects on the abducens nuclei, including a 
reduction in the firing rate.42 Using a rat model of infraorbital 
nerve constriction, Kitamura et al43 found that BT-A injected 
3 days following nerve injury not only reduced mechanical 
allodynia but also reduced exaggerated neurotransmitter 
release from trigeminal ganglion neurons.
Given the high-affinity binding of botulinum toxin to the 
peripheral cholinergic nerve terminals, many authors have 
hypothesized that any central effect of botulinum toxin was 
indirect; either related to an alteration in sensory input from 
the muscle spindles or as an effect of denervation on CNS 
plasticity.41,44 The possibility that BT-A could reach the CNS 
had been suggested in the 1970s, but it was felt that the retro-
grade axonal transport system was so slow that the toxin was 
likely to be inactive before it reached the cell body.28 However, 
in the last few years, studies have shown that at high doses, 
at least some amount of catalytically active BoNT-A may 
undergo retrograde transport to the motor nuclei supplying 
that nerve terminal.45 As axonal transport to the CNS within 
motor neurons would not necessarily explain a reduction in 
pain, a more recent study looked for similar evidence of ret-
rograde transport within sensory neurons. Matak et al46 used 
a rat model of formalin-induced facial pain and examined the 
effects of BT-A injected into the rat whisker pad or sensory 
trigeminal ganglion. They found that BT-A at either location 
reduced the phase II pain. When colchicine was given to block 
microtubule-dependent transport, the antinociceptive effect 
was prevented. They also found BT-A-truncated SNAP-25 in 
the medullary dorsal horn of the trigeminal nucleus   caudalis 
3 days following injection into the whisker pad.
Summary
The precise mechanism of BT-A as a migraine preventive 
is still unknown but remains an area of great interest and Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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ongoing research. Based on the available in vitro and in vivo 
models, it has been proposed that BT-A inhibits the release 
of pain-related neurotransmitters and neuropeptides such as 
substance P, CGRP, and glutamate from the peripheral termini 
of primary trigeminal and cervical afferents. This reduces 
peripheral sensitization. Because central sensitization results 
from ongoing input from pain fibers, the inhibition of these 
peripheral signals indirectly inhibits central sensitization. 
In addition, peripherally injected BT-A may be retrogradely 
transported along axons of peripheral nerves, allowing 
inhibitory effects at the level of the dorsal root ganglion and 
dorsal horn.28 Whatever the mechanism of action, it is the 
analgesic effects and low systemic side effects observed in 
clinical trials that have led to the growing use of botulinum 
toxin for migraine headache.
Clinical efficacy studies
As mentioned previously, the present discussion analyzes data 
from randomized, double-blind, placebo-controlled studies 
published in the English literature researching onabotu-
linumtoxinA specifically in adult migraine prophylaxis 
(see Table 2).47–57 Although small case series have shown 
encouraging results using onabotulinumtoxinA in pediatric 
chronic migraine,58,59 to this date no placebo-controlled stud-
ies have been published in English literature.
episodic migraine
In the first randomized, double-blind, placebo-controlled 
study, Silberstein et al47 attempted to confirm Binder et al’s6 
findings. Subjects having two to eight moderate-to-severe 
migraines per month (with or without aura) were randomized 
to placebo or onabotulinumtoxinA (25 U or 75 U). Subjects 
received symmetrical injections into the frontalis, tempora-
lis, corrugator, and procerus muscles. The mean migraine 
frequencies per month at baseline in the placebo, 25 U, and 
75 U treatment groups were 4.8, 4.3, and 4.0, respectively. 
The study’s primary efficacy variable was met. There was a 
significantly greater reduction in the number of moderate-to-
severe migraines in the 25 U group than in the placebo group 
at Month 2 (placebo, −0.37; 25 U onabotulinumtoxinA, −1.57; 
P = 0.008) and Month 3 (placebo, −0.98; 25 U onabotulinum-
toxinA, −1.88; P = 0.042) after injection. For unclear reasons, 
the 75 U dose did not perform as well as the 25 U dose. The 
authors suspected that this was secondary to the lower migraine 
frequency at baseline in the 75 U treatment group.
Evers et al48 used different onabotulinumtoxinA doses 
with a specific focus on different injection sites. Sixty sub-
jects having two to eight migraine attacks were enrolled. 
Subjects were treated with either 100 U in the frontal and neck 
muscles or with 16 U in the frontal muscles and placebo in 
the neck muscles, or with placebo in all muscles. The primary 
efficacy parameter was not met. The rate of patients with at 
least a 50% reduction of migraine frequency was 30% in the 
group receiving 100 U, 30% in the group receiving 16 U, and 
25% in the group receiving placebo (P = 0.921). Regarding 
secondary efficacy parameters, the only significant differ-
ence observed was in the sum score of all accompanying 
symptoms. In the 16 U group, but not in the 100 U group, 
the accompanying symptoms (photophobia, phonophobia, 
nausea, and vomiting) were significantly reduced by 29% 
in Month 3 compared with a reduction of 5% in the placebo 
group (P = 0.048; posthoc test). Similar to Silberstein et al’s47 
study, it was the low-dose treatment group in which Evers 
et al48 were able to observe a significant finding, leading them 
to consider the total dosage of onabotulinumtoxinA a less 
important variable than other parameters such as injection 
sites and patient selection.
In a series of three sequential randomized, double-blind 
studies, Elkind et al49 further explored onabotulinumtoxinA 
for migraine prophylaxis in subjects suffering four to eight 
moderate-to-severe migraines per month. In study I, patients 
were randomized to placebo or onabotulinumtoxinA into 
frontal, glabellar, and temporal muscle at a dose of 7.5 U, 
25 U, or 50 U. In study II, completers who received placebo 
or onabotulinumtoxinA 7.5 U were randomized to receive 
two treatments of either 25 U or 50 U onabotulinumtoxinA, 
whereas patients who had received onabotulinumtoxinA 
25 U or 50 U continued the same dose for two additional 
treatments. Completers entered study III, where they were 
randomized to placebo or continued treatment with 25 U or 
50 U. All treatments across the three studies were admin-
istered at 4 month intervals. The primary efficacy measure 
was not met. Migraine frequency was not different among 
treatment groups at any visit in any of the studies (assessed as 
change from baseline, all P $ 0.201). There was no statisti-
cally significant effect of onabotulinumtoxinA at any time. 
When comparing their results with more encouraging results 
obtained in chronic daily headache (CDH) trials (with many 
chronic migraine patients),60 Elkind et al49 suggested that 
perhaps those with a greater frequency of migraine attacks 
are more responsive to onabotulinumtoxinA than subjects 
with episodic migraine.
Aurora et al50 performed a phase II trial using the 
“follow-the-pain” injection protocol. Instead of having 
the onabotulinumtoxinA injection sites and doses already 
fixed (referred to as the “fixed-site, fixed-dose” approach), Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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they allowed the investigator to define the injection sites 
and doses based on pain distribution and severity (except 
the occipitalis muscle, where dosing was fixed). A total 
of 369 subjects were randomized to three treatments with 
onabotulinumtoxinA 110–260 U or placebo at 90 day 
  intervals. OnabotulinumtoxinA did not show superiority over 
placebo in the primary efficacy measure. At Day 180, the 
mean change from baseline in migraine frequency per 30 day 
period was −2.4 in the onabotulinumtoxinA group compared 
with −2.2 in the placebo group (P . 0.999). There were no 
statistically significant differences between treatment groups. 
In a post hoc analysis, however, in the group of patients 
experiencing a higher baseline frequency ($12 headache 
days), patients receiving onabotulinumtoxinA experienced 
a significant reduction in migraine frequency, with a mean 
change from baseline of –4 headache episodes compared 
with –1.9 for the placebo patients (P = 0.048). Although 
the Day 180 time point was the only time point at which the 
between-group difference reached statistical significance, a 
consistent trend was observed within this subgroup of patients 
favoring onabotulinumtoxinA throughout the study.
In a small 3 month study, 32 subjects with four to eight 
migraine attacks per month were randomized to symmetrical 
injections of 50 U of onabotulinumtoxinA in three pericranial 
muscle regions (frontalis, temporalis, and glabellar) versus 
placebo.51 The primary efficacy parameter was frequency of 
attacks per 4 weeks, and the effect on this was difficult to 
determine due to inconsistencies in the text of the manuscript. 
The secondary efficacy parameter was defined as severity 
of attacks, and the authors state that 75% of patients in the 
onabotulinumtoxinA group reported a marked improvement 
in the intensity of headaches from a “moderate-severe” cat-
egory to “complete relief-mild” category, whereas none in 
the placebo group noted this improvement (P , 0.05).
Relja et al54 used a 30 day placebo run-in to divide 495 
patients into placebo responders (n = 173) and placebo 
nonresponders (n = 322). They then injected 225 U, 150 U, 
or 75 U of onabotulinumtoxinA or placebo using a fixed-
site, fixed-dose seven-site approach in pericranial and neck 
muscles. Patients received additional treatments at Day 90 
and Day 180 and returned for follow-up visits at 30 day 
intervals following each treatment through Day 270. At Day 
180, the primary endpoint, the mean change from baseline 
in the frequency of migraine episodes in the placebo non-
responders stratum per 30 day period was −1.6, −1.7, −1.5, 
and −1.4 in the onabotulinumtoxinA 225 U, 150 U, 75 U, 
and placebo groups, respectively. The differences between 
the groups were not statistically significant (P = 0.817). Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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A strong placebo response was evident in this trial. According 
to the authors, this could have been secondary to the uneven 
randomization scheme with a greater number of active treat-
ment arms instead of an even 1:1 randomization.
Saper et al55 compared different injection sites and 
doses of onabotulinumtoxinA in patients with four to 
eight moderate-to-severe headaches per month. A total of 
232 patients were randomized, with 45 assigned to placebo 
and 187 assigned to onabotulinumtoxinA (n = 44 frontal, 
n = 45 temporal, n = 49 glabellar, n = 49 all three sites or 
“FTG”). The primary efficacy variable was frequency of 
migraine headaches, with Day 60 specified as the primary 
endpoint. Following intervention, baseline frequency ratings 
were 5.6 (FTG), 5.7 (frontal), 5.9 (temporal), 5.3 (glabellar), 
and 5.5 (placebo) migraine headaches per month (P = 0.399). 
No statistically significant among-group differences were 
observed for decreases from baseline in the frequency of 
migraines of any severity at the 30, 60, or 90 day follow-up 
visit (all P $ 0.411). According to the authors, low onabotu-
linumtoxinA dose, lack of posterior head and neck muscle 
injections, allowance of other preventive medication use, 
and exclusion of patients with chronic migraine may all have 
been reasons for a negative trial.
To conclude, although results from Silberstein et al’s47 
original study in episodic migraine were encouraging, the 
available data from randomized, double-blind, placebo-
controlled studies do not convincingly show onabotulinum-
toxinA to be effective in the prevention of episodic migraine. 
Based on the current evidence, a report of the Therapeutics 
and Technology Assessment Subcommittee of the American 
Academy of Neurology has labeled onabotulinumtoxinA as 
probably ineffective in episodic migraine treatment.61
Chronic migraine
In a small study from Freitag et al,53 41 patients were random-
ized to onabotulinumtoxinA 100 U or placebo using a fixed-
site, fixed-dose paradigm at the glabella, temporal, frontal, 
suboccipital, and trapezius muscles. Patients were excluded 
if they were overusing analgesics or caffeine. The primary 
efficacy parameter was the change in monthly migraine 
frequency per 4 week assessment period over 4 months 
compared with baseline. OnabotulinumtoxinA injections 
were found to be superior to placebo in terms of reduction of 
headache attack frequency, reducing headaches from 13.8 to 
10.1 per month (P = 0.001, correlation coefficient = 0.695), 
compared with the placebo arm that actually noted a rise in 
headache frequency from 14.6 to 15.4 per month (P = 0.046, 
correlation coefficient = 0.475). In addition, six of 18 (33%) 
completers on onabotulinumtoxinA had at least a 50% 
  reduction in migraine episodes compared with three of 18 
(16.7%) placebo patients.
The PREEMPT 1 (Phase III Research Evaluating Migraine 
Prophylaxis Therapy-1) trial56 had a 24 week, double-blind, 
parallel-group, placebo-controlled phase followed by a 32 week, 
open-label phase. A total of 679 patients were randomized 1:1 
to onabotulinumtoxinA or placebo injected every 12 weeks. 
Two cycles of injections were administered. Two-thirds of 
patients were overusing acute medications, though patients 
using frequent opiates were avoided at enrollment. No phar-
macologic prophylactics were allowed.   OnabotulinumtoxinA 
or placebo was administered using fixed-site, fixed-dose 
injections across seven head and neck muscle areas (cor-
rugator, procerus, frontalis, temporalis, occipitalis, cervical 
paraspinal, and trapezius). At the investigator’s discretion, 
an additional 40 U could be administered using a follow-the-
pain strategy. The primary endpoint was mean change from 
baseline in frequency of headache episodes for the 28 day 
period ending with Week 24. No significant between-group 
difference for onabotulinumtoxinA versus placebo was seen 
for this (−5.2 vs −5.3; P = 0.344). A high placebo response 
rate was observed.   Significant between-group differences 
for onabotulinumtoxinA were observed for the secondary 
endpoints headache days (P = 0.006) and migraine days 
(P = 0.002) at all time points (including Week 24). The trial 
design of PREEMPT 2 was identical to its predecessor’s and 
randomized 705 patients to either onabotulinumtoxinA or 
placebo.57 Similar to PREEMPT 1, most patients overused pain 
medications at baseline. The primary endpoint in PREEMPT 
2 was the mean change from baseline in frequency of 
headache days for the 28 day period ending with Week 24. 
  OnabotulinumtoxinA was significantly superior to placebo for 
this endpoint (−9.0 headache days with onabotulinumtoxinA 
vs −6.7 placebo, P , 0.001; mean intergroup difference −2.3 
[95% confidence interval −3.25, −1.31]).
Pooled analyses from PREEMPT 1 and 2 (1384 patients) 
demonstrated a mean decrease from baseline in frequency of 
headache days, with statistically significant between-group 
differences favoring onabotulinumtoxinA over placebo at 
Week 24 (−8.4 vs −6.6; P , 0.001) and at all other time 
points.62 Significant differences favoring onabotulinumtoxinA 
were also observed for a number of secondary efficacy vari-
ables, including reductions in moderate or severe headache 
days (P , 0.001), cumulative hours of headache on headache 
days (P , 0.001), headache episodes (P , 0.009), the propor-
tion of patients with a severe headache impact test-6 score 
(P , 0.001), and migraine episodes (P , 0.004).Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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To conclude, available randomized, double-blind, 
placebo-controlled trials suggest that onabotulinumtoxinA 
is effective in chronic migraine prophylaxis.53,62 It is impor-
tant to note, however, that the therapeutic gain over placebo 
for many of the PREEMPT trials’ outcomes was modest, 
even if statistically significant.56,57,62 As an example, in the 
pooled analysis, treatment with onabotulinumtoxinA led 
to a statistically significant reduction of headache days per 
28 days compared with placebo (8.4 vs 6.6), but the absolute 
difference between the two groups was small (1.8 days);62 
supporting the utility of onabotulinumtoxinA injection as 
moderately superior to placebo for the treatment of chronic 
migraine. This, the high cost of the toxin, and the need for 
an experienced clinician to administer onabotulinumtoxinA 
have led some authors to consider it as a second-line chronic 
migraine prophylactic therapy.63
Still, the excellent tolerability of onabotulinumtoxinA 
makes it an extremely attractive alternative for patients 
who fail to tolerate, and therefore discontinue, traditional 
oral prophylactics. In comparison with topiramate, for 
example, Mathew and Jaffri64 reported that patients receiv-
ing onabotulinumtoxinA had fewer adverse effects leading 
to discontinuation (7.7%) than patients in the topiramate 
group (24.1%). In another study, more than half of the study 
population had discontinued oral migraine prophylaxis 
within 3 months after commencing onabotulinumtoxinA.65 
Because it is injected, compliance appears to be less of an 
issue when comparing onabotulinumtoxinA with oral pro-
phylactics.62   OnabotulinumtoxinA may be a useful treatment 
option for headache patients demonstrating poor compliance, 
adherence, or adverse event profile with oral prophylactic 
regimens.66
Unspecified migraine subtype or CDH
A small study looked at the effect of higher doses of onabotu-
linumtoxinA on migraine,52 without specifying episodic or 
chronic migraine. Forty-nine patients with more than five 
migraine attacks per month were randomized to receive either 
onabotulinumtoxinA or placebo into corrugator, frontalis, 
temporalis, sternocleidomastoid, occipitalis, and posterior 
neck muscles. The proportion of episodic versus chronic 
migraine patients is uncertain. The two standardized dosing 
schemes based on patient weight were 135 U for those ,65 kg 
and 205 U for those $65 kg. The primary outcome measure 
was the average frequency of headache days measured during 
30 day blocks for 3 months. The secondary outcome measure 
was the severity of attacks. No significant differences were 
observed between control and test groups at baseline on 
these measures. Importantly, a high dropout rate of 17 (34%) 
led to a small sample size to be analyzed, which may have 
attenuated the power to detect any potential main effects of 
onabotulinumtoxinA in the prevention of migraine.
“Chronic daily headache” (CDH) is a descriptive term, 
generally defined by $15 headache days per month,67 that 
encompasses multiple headache diagnoses, including chronic 
migraine, chronic tension-type headache, new daily persis-
tent headache, hemicrania continua, and others. Randomized, 
placebo-controlled studies evaluating onabotulinumtoxinA 
in CDH have yielded mixed results and are difficult to ana-
lyze, given the heterogeneity of the headache syndromes 
represented. For instance, a study by Ondo et al67 noted 
that only 14 of their 60 enrolled CDH subjects had chronic 
migraine, and the rest had chronic tension-type headache. 
This makes it difficult to draw strong conclusions from the 
study’s somewhat positive results.60,68 Other investigators 
used onabotulinumtoxinA in a fixed-site approach for CDH 
prophylaxis in 702 enrolled patients, 53% of whom had 
a confirmed “transformed” (chronic) migraine diagnosis 
while the rest (47%) had an unspecified or alternative CDH 
subtype.69 The primary efficacy endpoint (mean change 
from baseline in the frequency of headache-free days for the 
30 day period ending on Day 180) was not met, although 
at Day 240 the decrease in headache frequency was signifi-
cantly greater for the onabotulinumtoxinA 225 U and 150 
U groups compared with placebo. No subgroup statistical 
analysis was done based on CDH subtype. Another attempt 
to establish onabotulinumtoxinA as a probable effective CDH 
prophylactic using a follow-the-pain approach in a dose of 
105–260 U failed to reach statistical significance for the 
primary efficacy measure (mean change from baseline in the 
frequency of headache-free days in a 30 day period), although 
a significantly higher percentage of onabotulinumtoxinA 
patients had a $50% headache day frequency decrease from 
baseline per 30 day period at Day 180 (32.7% vs 15.0%, 
P = 0.027), the secondary efficacy measure.60 In this study, 
most patients (61% of 355) reported a history of migraine. 
However, precise CDH subtypes were not known.
Safety and tolerability
OnabotulinumtoxinA has been fairly well tolerated across 
studies. Reported adverse events with onabotulinumtoxinA 
in these randomized trials were transient, and were most fre-
quently related to muscle weakness or pain at injections sites. 
Muscle weakness around the face and neck, for instance, has 
led to a higher number of patients in the onabotulinumtoxinA 
groups reporting neck pain, muscular weakness, eyelid Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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  ptosis, and diplopia. In the pooled analysis of the PREEMPT 
trials, only neck pain occurred, with an incidence of .5% 
(6.7% onabotulinumtoxinA group vs 2.2% placebo group). 
The most frequently reported side effects leading to discon-
tinuation of onabotulinumtoxinA injections were neck pain 
(0.6%), muscular weakness (0.4%), headache (0.4%), and 
migraine (0.4%).62
The safety of onabotulinumtoxinA in migraine manage-
ment during pregnancy and lactation has not been established. 
Most randomized, double-blind, placebo-controlled studies 
using onabotulinumtoxinA in migraine prophylaxis have 
excluded pregnant and lactating women. With the exception 
of a woman who discontinued the study at Day 145 because 
of pregnancy and subsequently delivered a healthy child,49 
no other pregnancy outcome has been reported in these trials. 
At present, onabotulinumtoxinA belongs to the pregnancy 
category C (risk cannot be ruled out) of the FDA and is not 
recommended during pregnancy.70
Outside of the studies included in this review, distant 
spread of onabotulinumtoxinA beyond the site of injection 
and systemic effects resembling botulism (dysphagia, breath-
ing difficulties, generalized muscle weakness, among others) 
appear to be rare but have been reported even at low doses.71 
Because of this, the FDA has required a boxed warning for 
all botulinum toxin products (see Figure 2).
Disability and health-related  
quality of life
It is well recognized that migraine attacks not only impair 
the individual’s ability to function during the attack but also 
may affect an individual’s functioning and overall well-being 
between attacks.1 Many of the randomized, controlled effi-
cacy trials attempted to assess whether onabotulinumtoxinA 
treatment impacted the patients’ migraine-related disability 
and health-related quality of life. The measuring instruments 
were not consistent throughout the efficacy studies, however, 
making comparison among them problematic. In some cases, 
the questionnaire used may not have been a validated tool or 
its source was not properly cited, further complicating the 
interpretation of their results.
Based on limited data available, there is some suggestion 
that onabotulinumtoxinA may improve the health-related 
quality of life in patients with chronic migraine. The 
PREEMPT trials looked at this using the Migraine-specific 
Quality of Life Questionnaire Version 2.1. Pooled analysis 
of the data from both trials showed that treatment with 
onabotulinumtoxinA significantly improved health-related 
quality of life (P , 0.001), as measured by changes from 
baseline in all three role function domains (restrictive, 
preventive, and emotional) at both time points evaluated 
(Weeks 12 and 24).62 Pooled analysis also demonstrated a 
clinically meaningful between-group difference for onabotu-
linumtoxinA versus placebo observed at Week 24 in mean 
change from baseline in total Headache Impact Test-6 score 
(2.4; P , 0.001), a score that measures headache-related 
disability. Freitag et al53 also noted a positive trend when 
examining the effect of onabotulinumtoxinA on Migraine 
Disability Assessment Scores, but the differences did not 
meet statistical significance.
Comparator studies
Small studies comparing onabotulinumtoxinA with other 
first-line migraine preventives are promising. A randomized, 
double-blind study of 59 migraineurs showed that patients 
receiving onabotulinumtoxinA with an oral placebo had 
similar improvements in migraine disability scores, and 
similar reductions in headache days to patients receiving 
divalproex sodium and placebo injections.72 Another study 
of 72 patients showed that 250 U of onabotulinumtoxinA 
had similar efficacy to 25 mg or 50 mg of amitriptyline for 
chronic migraine.73 Finally, two recent randomized, placebo-
controlled trials (59 and 60 patients) compared up to 200 U 
of onabotulinumtoxinA with topiramate and concluded that 
onabotulinumtoxinA had similar benefit to topiramate in the 
treatment of chronic migraine.64,74
Dosing and administration
Ample variation in onabotulinumtoxinA dose, injection 
sites, and strategy (“fixed-site, fixed-dose” or “follow-
the-pain”) has been seen throughout the trials. The large 
WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of BOTOX and all botulinum toxin products may spread from the area of the injection to produce 
symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after
injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death.
The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults,
particularly in those patients who have an underlying condition that would predispose them to these symptoms
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multicenter PREEMPT trials used a fixed-site, fixed-dose 
injection paradigm, with additional follow-the-pain sites 
considered depending on individual symptoms.75 The PRE-
EMPT paradigm has proven to be safe, well tolerated, and 
more effective than placebo, and has been recommended by 
some authors as the evidence-based approach to optimize 
clinical outcomes for patients with chronic migraine.56,57,75 
Other authors have disputed the need for all of the injections 
sites included in the PREEMPT trials, and advocate further 
studies to identify the best injection strategy.76
Until future studies establish the optimal dose, injec-
tion sites, and protocol for onabotulinumtoxinA in chronic 
migraine prophylaxis, the standardized 155 U injection 
protocol tested in the PREEMPT trials is a great and wel-
comed advance. Unfortunately, the recommended 155 U dose 
creates obvious problems in resource utilization and cost 
effectiveness. In the US, onabotulinumtoxinA is available in 
  single-use 50 U, 100 U, or 200 U vials. If one were to routinely 
use the 155 U protocol, this could lead to a significant waste 
of nonreusable product.
At our institution, most chronic migraine patients get 
a 150 U protocol (Figure 3, Table 3) in a fixed-site, fixed-
dose fashion targeting similar injection sites to those in the 
PREEMPT injection protocol. This is occasionally combined 
with an additional follow-the-pain site on an individual case 
basis. There is no indisputable evidence yet supporting that 
adding the follow-the-pain strategy is superior to the 155 U 
fixed-site, fixed-dose protocol alone. OnabotulinumtoxinA 
injections are administered typically every 12 weeks. More 
frequent administration is avoided to minimize the formation 
of neutralizing antibodies, which can affect onabotulinum-
toxinA efficacy.26
Conclusion
Based on the available data, onabotulinumtoxinA has not 
been convincingly shown to be effective in the prevention of 
episodic migraine. In chronic migraine prophylaxis, however, 
available randomized, double-blind, placebo-controlled trials 
suggest that onabotulinumtoxinA is effective. The injected 
form and excellent tolerability of onabotulinumtoxinA makes 
it an extremely attractive alternative for chronic migraine 
patients who have demonstrated poor tolerance or poor 
compliance with traditional oral prophylactics. Although 
the mechanisms through which onabotulinumtoxinA may 
exert its benefit remain uncertain, onabotulinumtoxinA is 
a welcome addition to the available treatment options for 
chronic migraine, which is often a disabling and difficult-
to-manage condition.
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Figure 3 OnabotulinumtoxinA injection sites used by the authors (see Table 3 for dosing).
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Table 3   Standard  fixed-site,  fixed-dose  150  U  protocol  for 
onabotulinumtoxinA currently used by the authors at the time of 
this manuscript’s publication
•   5.0 U into each corrugator muscle and into the procerus muscle
    One injection site per muscle (15.0 U total)
•   5.0 U into the right and left superior frontalis muscle
    Two injection sites per muscle (10 U total)
•   12.5 U into each temporalis muscle
    Two injection sites per muscle (25 U total)
•   12.5 U into each splenius capitis muscle
      Two injection sites per muscle administered as two-thirds of 
12.5 U (8.3 U) at superior injection site (near muscle insertion) and 
one third (4.2 U) at mid-belly of muscle to minimize neck weakness 
(25 U total)
•   12.5 U into each occipitalis muscle
    Two injection sites per muscle (25 U total)
•   25 U into each trapezius muscle
    Three injection sites per muscle (50 U total)Neuropsychiatric Disease and Treatment 2012:8 submit your manuscript | www.dovepress.com
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